Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Journal of Biopharmaceutical Statistics
|
December 12, 2022
Addressing statistical issues when leveraging external control data in pediatric clinical trials using Bayesian dynamic borrowing
Emmanouil Spanakis, Martina Kron, Mareike Bereswill, et al.
Journal of the American Academy of Dermatology
|
July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis
Alan Menter, Diamant Thaçi, Kim A Papp, et al.
Journal of Crohn'S & Colitis
|
May 8, 2022
Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial
Sven Stodtmann, Mong-Jen Chen, Lucia Siovitz, et al.
Inflammatory Bowel Diseases
|
February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry
Edward V Loftus, Walter Reinisch, Remo Panaccione, et al.
Dermatology and Therapy
|
August 18, 2017
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
Alan Menter, Diamant Thaçi, Jashin J Wu, et al.
United European Gastroenterology Journal
|
May 13, 2022
Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
Ailsa Hart, Geert D'Haens, Mareike Bereswill, et al.
The American Journal of Gastroenterology
|
June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry
Geert DʼHaens, Walter Reinisch, Remo Panaccione, et al.
The Lancet. Gastroenterology & Hepatology
|
June 21, 2021
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study
Nicholas M Croft, William A Faubion, Subra Kugathasan, et al.
Journal of Crohn'S & Colitis
|
October 6, 2017
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA
Simon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Arthritis Care & Research
|
August 18, 2019
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results
Hermine I Brunner, Kabita Nanda, Mary Toth, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Journal of Biopharmaceutical Statistics
|
December 12, 2022
Addressing statistical issues when leveraging external control data in pediatric clinical trials using Bayesian dynamic borrowing
Emmanouil Spanakis, Martina Kron, Mareike Bereswill, et al.
Journal of the American Academy of Dermatology
|
July 21, 2015
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis
Alan Menter, Diamant Thaçi, Kim A Papp, et al.
Journal of Crohn'S & Colitis
|
May 8, 2022
Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial
Sven Stodtmann, Mong-Jen Chen, Lucia Siovitz, et al.
Inflammatory Bowel Diseases
|
February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry
Edward V Loftus, Walter Reinisch, Remo Panaccione, et al.
Dermatology and Therapy
|
August 18, 2017
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
Alan Menter, Diamant Thaçi, Jashin J Wu, et al.
United European Gastroenterology Journal
|
May 13, 2022
Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
Ailsa Hart, Geert D'Haens, Mareike Bereswill, et al.
The American Journal of Gastroenterology
|
June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry
Geert DʼHaens, Walter Reinisch, Remo Panaccione, et al.
The Lancet. Gastroenterology & Hepatology
|
June 21, 2021
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study
Nicholas M Croft, William A Faubion, Subra Kugathasan, et al.
Journal of Crohn'S & Colitis
|
October 6, 2017
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA
Simon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Arthritis Care & Research
|
August 18, 2019
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results
Hermine I Brunner, Kabita Nanda, Mary Toth, et al.
Page
of 1